Drug Type Small molecule drug |
Synonyms Aclatonium napadisilate (JAN), SKF-100916-J, TM-723 + [1] |
Target |
Mechanism mAChRs agonists(Muscarinic acetylcholine receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (01 Jan 1981), |
Regulation- |
Molecular FormulaC30H46N2O14S2 |
InChIKeyHELVYVGHOJPCEV-UHFFFAOYSA-L |
CAS Registry55077-30-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Gastrointestinal motility disorder | JP | 01 Jan 1981 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Biliary Dyskinesia | Phase 1 | CN | 22 Dec 2017 | |
Feeding and Eating Disorders | Phase 1 | CN | 22 Dec 2017 | |
Gastritis | Phase 1 | CN | 22 Dec 2017 | |
Nausea | Phase 1 | CN | 22 Dec 2017 | |
Vomiting | Phase 1 | CN | 22 Dec 2017 |
Not Applicable | 92 | jbnsjxunwq(zonknwnuwz) = aucblnedlv zvjwempsii (mclpqcapji ) | - | 01 Apr 2011 | |||
jbnsjxunwq(zonknwnuwz) = zahrnnuknh zvjwempsii (mclpqcapji ) |